MX2020007271A - Sales y cristales novedosos. - Google Patents
Sales y cristales novedosos.Info
- Publication number
- MX2020007271A MX2020007271A MX2020007271A MX2020007271A MX2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A MX 2020007271 A MX2020007271 A MX 2020007271A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- novel salts
- utan
- quinoxalin
- pyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La divulgación provee formas de sal clorhidrato nuevas, farmacéuticamente aceptables, de 1-(4-fluoro-fenil)-4-((6bR,10aS)- 3-metil-2,3,6b,9,10,10a-hexahidro-1H,7H-pirido[3',4':4,5]pirrolo[ 1,2,3-de]quinoxalin-8-il)-butan-1-ona, junto con métodos de preparación y uso de las mismas, y composiciones farmacéuticas que las comprenden.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762563341P | 2017-09-26 | 2017-09-26 | |
PCT/US2018/052922 WO2019067591A1 (en) | 2017-09-26 | 2018-09-26 | NEW SALTS AND CRYSTALS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007271A true MX2020007271A (es) | 2020-08-17 |
Family
ID=65903143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007271A MX2020007271A (es) | 2017-09-26 | 2018-09-26 | Sales y cristales novedosos. |
Country Status (6)
Country | Link |
---|---|
US (2) | US11440911B2 (es) |
EP (1) | EP3687535A4 (es) |
JP (1) | JP2020535231A (es) |
CN (1) | CN111107847A (es) |
MX (1) | MX2020007271A (es) |
WO (1) | WO2019067591A1 (es) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
CA2374239A1 (en) | 1999-06-15 | 2000-12-21 | Albert J. Robichaud | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
EP1343791A2 (en) | 2000-12-20 | 2003-09-17 | Bristol-Myers Squibb Company | Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
CA2445159C (en) | 2001-04-24 | 2012-09-11 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
JP2006528187A (ja) | 2003-07-21 | 2006-12-14 | スミスクライン ビーチャム コーポレーション | (2S,4S)−4−フルオロ−1−[4−フルオロ−β−(4−フルオロフェニル)−L−フェニルアラニル]−2−ピロリジンカルボニトリルp−トルエンスルホン酸塩及びその無水結晶形態 |
US20100204470A1 (en) * | 2006-06-27 | 2010-08-12 | Sandoz Ag | method for salt preparation |
CN101796051B (zh) * | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
CN101842010A (zh) | 2007-08-01 | 2010-09-22 | 梅迪维新神经学公司 | 使用抗精神病的组合治疗产品来治疗精神分裂症的方法和组合物 |
PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
CN102105059B (zh) * | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
RU2591194C2 (ru) | 2010-04-22 | 2016-07-10 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
WO2013155504A1 (en) * | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2893621T3 (es) | 2013-12-03 | 2022-02-09 | Intra Cellular Therapies Inc | Métodos para el tratamiento de los síntomas residuales de la esquizofrenia |
US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2017172811A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
WO2018031535A1 (en) | 2016-08-09 | 2018-02-15 | Assia Chemical Industries Ltd. | Solid state forms of lumateperone ditosylate salt |
CN116327770A (zh) | 2017-03-24 | 2023-06-27 | 细胞内治疗公司 | 新组合物和方法 |
CN110636845A (zh) | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
EP3717484A4 (en) | 2017-11-27 | 2021-08-04 | Egis Gyógyszergyár Zrt. | PROCESS FOR THE PRODUCTION OF LUMATEPERON AND ITS SALT |
JP7483671B2 (ja) | 2018-06-11 | 2024-05-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ-カルボリン類合成 |
-
2018
- 2018-09-26 US US16/649,515 patent/US11440911B2/en active Active
- 2018-09-26 JP JP2020538775A patent/JP2020535231A/ja active Pending
- 2018-09-26 EP EP18860411.0A patent/EP3687535A4/en active Pending
- 2018-09-26 WO PCT/US2018/052922 patent/WO2019067591A1/en unknown
- 2018-09-26 CN CN201880061554.9A patent/CN111107847A/zh active Pending
- 2018-09-26 MX MX2020007271A patent/MX2020007271A/es unknown
-
2022
- 2022-07-28 US US17/815,843 patent/US20220363682A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3687535A4 (en) | 2021-06-09 |
US20200247805A1 (en) | 2020-08-06 |
EP3687535A1 (en) | 2020-08-05 |
US11440911B2 (en) | 2022-09-13 |
WO2019067591A1 (en) | 2019-04-04 |
JP2020535231A (ja) | 2020-12-03 |
US20220363682A1 (en) | 2022-11-17 |
CN111107847A (zh) | 2020-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013116A (es) | Sales y cristales novedosos. | |
MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
MX2022010797A (es) | Composiciones novedosas y metodos. | |
CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
MX2018015422A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridini lo. | |
SA521430638B1 (ar) | H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية | |
WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
PH12018500047B1 (en) | Notch pathway signaling inhibitor compounds | |
PH12017501816A1 (en) | Azabensimidazoles and their use as amp a receptor modulators | |
MY192216A (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
TW201613864A (en) | Novel compounds | |
MX2022013274A (es) | Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util. | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
MY194711A (en) | Novel annelated phenoxyacetamides | |
MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
NZ741553A (en) | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | |
NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
MX2021006886A (es) | Dispersiones solidas amorfas. | |
PH12018501563A1 (en) | Indane derivatives as mglur7 modulators |